A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

被引:45
|
作者
Pantuck, A. J. [1 ]
Pettaway, C. A. [2 ]
Dreicer, R. [3 ]
Corman, J. [4 ]
Katz, A. [5 ]
Ho, A. [5 ]
Aronson, W. [1 ,6 ]
Clark, W. [7 ]
Simmons, G. [8 ]
Heber, D. [1 ,9 ]
机构
[1] Univ Calif Los Angeles, Dept Urol, Inst Urol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Winthrop Univ Hosp, Garden City, NY USA
[6] VA Med Ctr Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[7] Alaska Clin Res Ctr, Anchorage, AK USA
[8] Five Valleys Urol, Missoula, MT USA
[9] Univ Calif Los Angeles, Dept Med & Clin Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
MANGANESE SUPEROXIDE-DISMUTASE; FACTOR-KAPPA-B; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; PHASE-II; GROWTH; CARCINOGENESIS; RADIATION; JUICE; RISK;
D O I
10.1038/pcan.2015.32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2: 1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P < 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P > 0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [1] A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer
    A J Pantuck
    C A Pettaway
    R Dreicer
    J Corman
    A Katz
    A Ho
    W Aronson
    W Clark
    G Simmons
    D Heber
    Prostate Cancer and Prostatic Diseases, 2015, 18 : 242 - 248
  • [2] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF POMEGRANATE EXTRACT ON RISING PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN FOLLOWING PRIMARY THERAPY FOR PROSTATE CANCER
    Pantuck, Allan
    Pettaway, Curtis
    Dreicer, Robert
    Corman, John
    Ho, Andrew
    Katz, Aaron
    Aronson, William
    Clark, William
    Simmons, Garrick
    Heber, David
    JOURNAL OF UROLOGY, 2015, 193 (04): : E57 - E57
  • [3] Randomized double-blind, placebo-controlled, crossover study of men with prostate cancer and rising PSA:: Effectiveness of a dietary supplement
    Schröder, FH
    Roobol, MJ
    Boevé, ER
    De Mutsert, R
    Verwillegen, W
    Zuidgeest, S
    Wildhagen, MF
    Van Helvoort, A
    JOURNAL OF UROLOGY, 2004, 171 (04): : 334 - 335
  • [4] Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA:: Effectiveness of a dietary supplement
    Schröder, FH
    Roobol, MJ
    Boevé, ER
    de Mutsert, R
    Zuijdgeest-Van Leeuwen, SD
    Kersten, I
    Wildhagen, MF
    van Helvoort, A
    EUROPEAN UROLOGY, 2005, 48 (06) : 922 - 931
  • [5] A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
    Paller, C. J.
    Ye, X.
    Wozniak, P. J.
    Gillespie, B. K.
    Sieber, P. R.
    Greengold, R. H.
    Stockton, B. R.
    Hertzman, B. L.
    Efros, M. D.
    Roper, R. P.
    Liker, H. R.
    Carducci, M. A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (01) : 50 - 55
  • [6] A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
    C J Paller
    X Ye
    P J Wozniak
    B K Gillespie
    P R Sieber
    R H Greengold
    B R Stockton
    B L Hertzman
    M D Efros
    R P Roper
    H R Liker
    M A Carducci
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 50 - 55
  • [7] Dietary intervention in prostate cancer patients:: PSA response in a randomized double-blind placebo-controlled study
    Kranse, R
    Dagnelie, PC
    van Kemenade, MC
    de Jong, FH
    Blom, JHM
    Tijburg, LBM
    Weststrate, JA
    Schröder, FH
    INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (05) : 835 - 840
  • [8] First double-blind placebo-controlled, multicenter, randomized trial of stabilized natural sulforaphane in men with rising PSA following radical prostatectomy.
    Cipolla, Bernard G.
    Mandron, Eric
    Lefort, Jean Marc
    Coadou, Yves
    Della Negra, Emmanuel
    Corbel, Luc
    Le Scodan, Romuald
    Mottet, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Pomegranate juice is not superior to placebo in patients with prostate cancer and rising PSA, results from a randomisided double-blind phase II study
    Stenner, F.
    Cathomas, R.
    Samaras, P.
    Liewen, H.
    Petrausch, U.
    Seifert, H.
    Sulser, T.
    Knuth, A.
    Muentener, M.
    Renner, C.
    ONKOLOGIE, 2012, 35 : 239 - 239
  • [10] A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis
    Hommes, Daan W.
    Erkelens, Willernien
    Ponsioen, Cyriel
    Stokkers, Pieter
    Raws, Erik
    van der Spek, Miram
    Ten Kate, Fiebo
    van Deventer, Sander J.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (05) : 522 - 526